Development of a novel nano-formulation for targeted delivery of anticancer agents in combination therapy.

Project Abstract

The study presents the design, synthesis, and evaluation of a novel nano-formulation aimed at targeted delivery of anticancer agents in combination therapy to enhance efficacy while minimizing systemic toxicity. A multifunctional nanoplatform was developed by co-encapsulating a synergistic pair of anticancer drugs within a biocompatible, stimuli-responsive polymeric matrix and decorating the surface with tumor-targeting ligands. The formulation leverages high drug loading, controlled release kinetics, and selective tumor accumulation through the enhanced permeability and retention (EPR) effect complemented by receptor-mediated endocytosis. Comprehensive physicochemical characterization confirmed nanoscale size distribution, uniform morphology, and robust stability under physiological conditions. Dynamic light scattering and zeta potential analyses demonstrated an average hydrodynamic diameter of approximately 120 nm with a near-neutral surface charge, factors conducive to prolonged circulation and reduced non-specific uptake. Differential scanning calorimetry and Fourier-transform infrared spectroscopy provided insights into drug–polymer interactions, indicating strong encapsulation within the hydrophobic cores and minimal drug crystallization, which supported sustained release profiles. In vitro release studies revealed time-dependent, pH-responsive drug release, with accelerated liberation in acidic environments typical of tumor microenvironments and intracellular endosomes. The dual-drug formulation exhibited synergistic cytotoxic effects against a panel of aggressive human cancer cell lines, with combination index values indicating strong synergy at clinically relevant concentrations. Flow cytometry and confocal microscopy confirmed enhanced cellular uptake and colocalization of the nano-formulation with lysosomal compartments, supporting a mechanism of endosomal escape and intracellular drug release. Mechanistic assays demonstrated induction of apoptosis via mitochondrial pathways, cell cycle arrest at the G2/M phase, and downregulation of pro-survival signaling cascades, accompanied by suppression of drug efflux transporters that often mediate resistance. For translational relevance, the formulation was evaluated in 3D tumor spheroids to approximate the extracellular matrix and heterogeneity present in solid tumors, where the nano-formulation achieved superior penetration and uniform distribution compared with free drug combinations. Pharmacokinetic profiling in a rodent model indicated favorable biodistribution with substantial tumor-to-normal tissue accumulation and a prolonged half-life, correlating with improved therapeutic indices. In vivo efficacy studies demonstrated significant tumor regression with reduced systemic toxicity, as evidenced by stable body weight, preserved organ function markers, and minimal histopathological alterations in major organs. Safety assessments included hematological analyses and cytokine profiling, revealing no overt immunogenic responses or systemic inflammatory reactions. The study also explored manufacturing scalability, highlighting reproducible batch-to-batch quality and compatibility with standard pharmaceutical processing techniques. Collectively, the proposed nano-formulation offers a versatile platform for co-delivery of anticancer agents, enabling dose-escalation flexibility, overcoming multidrug resistance, and achieving superior tumor-specific cytotoxicity while maintaining a favorable safety profile. Further optimization and long-term oncologic studies are recommended to facilitate clinical translation and assessment across diverse tumor genotypes.

Project Overview

What This Project Is About

---

A plain-language overview of the topic and what the project investigates. It looks at designing tiny carriers (nanoparticles) to deliver two anticancer drugs together directly to tumor cells, aiming to improve effectiveness while reducing side effects. The project explores how to make these carriers target cancer cells specifically, release drugs at the right time, and work better in combination than alone.

---

---

The Problem It Addresses

---

Many chemotherapy drugs affect healthy cells and tumors poorly respond when drugs are given separately. Using a single drug can lead to resistance, toxicity, and limited success. This project tackles how to combine two drugs in one tiny delivery system that homes in on cancer cells and releases each drug where it’s most needed.

---

---

Objectives of the Project

---

1. Explain what nano-formulations are and why they help cancer treatment.
2. Design a carrier capable of carrying two anticancer drugs.
3. Demonstrate targeting features that direct the carrier to tumor cells.
4. Show controlled release of both drugs in a simulated tumor environment.
5. Evaluate potential improvements in efficacy and safety compared to free drugs.

---

---

What You Will Do Step by Step

---

1. Review basic cancer biology and drug delivery concepts in simple terms.
2. Design a theoretical nanoparticle system and choose two drugs for co-delivery.
3. Explain targeting strategies and release mechanisms in plain language.
4. Outline a plan for synthesis and characterization steps (in silico or literature-based).
5. Describe data collection methods and how you would assess efficacy and safety.

---

---

Expected Outcome

An understandable explanation of the expected deliverable: a clear concept for a dual-drug nano-carrier with targeting and controlled release features, plus a plan for evaluating its potential benefits and limitations in early-stage studies.